Eloxx Pharmaceuticals, Inc. (ELOX)
NASDAQ
Real-time Data
01:30 PM
Day's Range
18.0152 wk Range
0.00011Overview - ELOX - Eloxx Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
30.55M
P/E (Trailing)
‪5.93‬
P/E (Forward)
‪-28.15‬
PEG Ratio
‪-0.08‬
Price / Book
‪1.73‬
EV / EBITDA
‪-4.86‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-113.75%‬
Return on Equity
‪50.34%‬
Ownership
Shares Outstanding
461.17K
Float
931.13K
Short % of Shares Outstanding
‪0.55%‬
Held by Insiders
‪26.28%‬
Held by Institutions
‪81.02%‬
Price stats
Beta
‪-160,692.25‬
50-Day Avg
‪14.32‬
200-Day Avg
‪14.19‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Average price target
‪$ 40.33‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ELOX - Eloxx Pharmaceuticals, Inc.
Peers - ELOX - Eloxx Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ELOXNASDAQEloxx Pharmaceuticals, Inc.66.28MMarket Cap+99.99%52-week change5.93P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt63.39BMarket Cap+30.55%52-week change39.65P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc32.12BMarket Cap-87.94%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE28.34BMarket Cap+7.12%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.52BMarket Cap+21.81%52-week change19.30P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.71BMarket Cap+38.32%52-week change-21.28P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.79BMarket Cap+11.28%52-week change174.00P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ELOX - Eloxx Pharmaceuticals, Inc.
About
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare disease and other serious conditions. The company’s current work centers on small-molecule genetic therapies, with lead programs aimed at addressing Alport syndrome, a rare kidney disorder, and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
